Cardiovascular disease

Heart
#Cardiovascular disease #Corticosteroids #Duchenne muscular dystrophy #Paediatrics #Santhera Pharmaceuticals

Vamorolone demonstrates unique action as a mineralocorticoid RA

Santhera Pharmaceuticals has announced positive results from the LIONHEART study, confirming vamorolone’s action as a mineralocorticoid receptor antagonist, which the company says sets it apart from other corticosteroids. The LIONHEART study in 30 healthy adult male subjects demonstrated a statistically significant increase in the urinary sodium/potassium… Read More

#News

Ozempic (semaglutide)
#Cardiovascular disease #Covid-19 #Diabetes #GLP-1 #Weight loss

Semaglutide reduces risk of all-cause death

Semaglutide has been found to reduce the rates of all-cause death, including as a result of Covid-19, in those who are overweight or have obesity and established cardiovascular disease without diabetes. The findings were published in JACC, the journal of the American College… Read More

#News #Trending News

#Cardiovascular disease #Collaboration #Drug discovery #Flagship Pioneering #Partnership #Pfizer

Flagship and Quotient partner on cardiovascular disease therapies

Pfizer has expanded its strategic partnership with Flagship Pioneering, adding two new research programmes with Flagship-founded Quotient Therapeutics. Under the collaboration, the companies will analyse somatic mutations that occur in diseased patient tissue to inform the discovery and development of therapies for cardiovascular and renal diseases. Read More

#Business & Investment #News

Human heart
#Cardiovascular disease #GLP-1 #Heart failure #Obesity #University College London #Weight loss

Semaglutide could also benefit patients with heart failure

A new study indicates that anti-obesity drug semaglutide helps prevent cardiac events among overweight people who have cardiovascular disease, even if they also have heart failure. The results follow a previous finding that weekly injections of semaglutide were linked to a 20% reduction in major adverse cardiac events (MACE) such… Read More

#News #Trending News

#Alzheimer's #Cardiovascular disease #GLP-1 #Liver disease #Nicotine addiction #Obesity #Weight loss

New DDW Highlights vodcast: 7 August 2024

Every week, DDW’s Megan Thomas narrates five key stories of the week to keep DDW subscribers up-to-date on the latest industry updates in the DDW Highlights podcast. It is now also available in a concise vodcast format.   GLP-1 receptor agonists have dominated… Read More

#News

#Alzheimer's #Cardiovascular disease #GLP-1 #Liver disease #Nicotine addiction #Obesity #Weight loss

New DDW Highlights podcast: 5 August 2024

The latest episode of the DDW Highlights podcast is now available to listen to below. DDW’s Megan Thomas narrates five key stories of the week to keep DDW subscribers up-to-date on the latest industry updates. GLP-1 receptor agonists have dominated the headlines this week, with data revealed on… Read More

#News

#Alzheimer's #Cardiovascular disease #GLP-1 #Liver disease #Nicotine addiction #Obesity #Weight loss

This week in drug discovery (29 July – 2 August) 

News round-up for 29 July – 2 August by DDW Senior Digital Content Editor Diana Spencer. GLP-1 receptor agonists have dominated the headlines this week, with data revealed on new potential beneficial effects of treatment with semaglutide and dual receptor agonists like pemvidutide. The top stories:… Read More

#News

Heart monitor
#Cardiovascular disease #Heart attack #MHRA #Novo Nordisk #Obesity #Weight loss

MHRA approves semaglutide to reduce risk of cardiovascular events

The UK Medicines and Healthcare products Regulatory Agency (MHRA) has approved a new indication for semaglutide (Wegovy) to reduce the risk of overweight and obese adults suffering from heart attacks or stroke. The GLP-1 receptor agonist is already approved for use in the treatment of obesity… Read More

#News #Regulatory

Cardiovascular system
#Cardiovascular disease #Therapeutic targets #University of Bristol

New treatment target for atheroschlerosis discovered

Scientists at the University of Bristol have uncovered a new disease driving mechanism which they are aiming to target to help treat the development of atherosclerotic plaques. The project to develop the new therapeutic, known as IMSET, is being led by Professor Jason Johnson, Professor of… Read More

#News

#Cardiovascular disease #Diabetes #GLP-1 #UT Southwestern #Weight loss

Data confirms that semaglutide lowers blood pressure

US scientists have released new data supporting initial findings that diabetes and weight loss drug semaglutide (Wegovy/Ozempic) lowers cardiovascular risk regardless of blood sugar. A weekly dose of semaglutide 2.4mg significantly reduced the risk of major adverse cardiovascular events (MACEs) in people with overweight… Read More

#News #Trending News

#Cardiovascular disease #Cell and gene therapy #Cell therapy #circular RNAs #Gene therapy

New DDW Highlights podcast: 21 May 2024

The latest episode of the DDW Highlights podcast is now available to listen to below. DDW’s Megan Thomas narrates five key stories of the week to keep DDW subscribers up-to-date on the latest industry updates.  From a weight loss drug that prevents heart attacks and a gene therapy that… Read More

#News

#Cardiovascular disease #Cell and gene therapy #Cell therapy #circular RNAs #Gene therapy

This week in drug discovery (13-16 May) 

News round-up for 13-16 May by DDW Senior Digital Content Editor Diana Spencer. From a weight loss drug that prevents heart attacks and a gene therapy that restores hearing, to a vaccine that can treat viruses that don’t exist yet, our chosen news stories this week all represent… Read More

#News

Patient using blood pressure monitor
#Cardiovascular disease #Novo Nordisk #Obesity #University College London #Weight loss

Ozempic could be a gamechanger for cardiovascular disease

Semaglutide (the active ingredient in Wegovy and Ozempic) can produce clinically meaningful weight loss and delivers significant cardiovascular benefits, according to two studies presented at the European Congress on Obesity (ECO). The studies are based on the Semaglutide and Cardiovascular Outcomes (SELECT) trial, the largest and… Read More

#News #Trending News

Novo Nordisk head office
#Cardior Pharmaceuticals #Cardiovascular disease #Mergers and acquisitions #Novo Nordisk

Novo Nordisk acquires cardiovascular therapies developer

Novo Nordisk has acquired Cardior Pharmaeuticals for up to €1.025 billion, including an upfront payment and additional payments if certain milestones are achieved. Cardior is focused on the discovery and development of therapies that target RNA to prevent, repair and reverse diseases of the heart. Read More

#Business & Investment #News

#Cardiovascular disease #FDA #Hypertension #Idorsia #Phase II trial

FDA approval represents ‘transformational progress’ in hypertension

The US Food and Drug Administration (FDA) has approved Tryvio (aprocitentan) for the treatment of hypertension in combination with other antihypertensive drugs, to lower blood pressure in adult patients who are not adequately controlled on other drugs. Tryvio (aprocitentan) is an endothelin receptor antagonist that inhibits… Read More

#News #Regulatory #Trending News

Cardiovascular system
#Cardiovascular disease #Immunology / Virology & Vaccines #Preclinical investigations #Vaxxinity

Vaccine successfully lowers cholesterol in preclinical studies

New studies have demonstrated that Vaxxinity’s vaccine VXX-401 reproducibly lowers low-density lipoprotein cholesterol (LDL-C) in non-human primates. The results support the continued clinical development of VXX-401 as a candidate for the treatment of hypercholesterolemia and prevention of atherosclerotic cardiovascular disease. VXX-401 is a synthetic… Read More

#News